Compare Analog Devices, Inc. (ADI) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Alnylam Pharmaceuticals, Inc. — how do they compare? Analog Devices, Inc. trades at $384 (market cap $187.67B), while Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B). The key difference: Analog Devices, Inc. is far larger — about 6.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Analog Devices, Inc. pays a 1.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ADI | ALNY | |
|---|---|---|
Market Cap | $187.67B | $29.60B |
Sector | Technology | Health |
52-Week High | $445.48 | $491.22 |
52-Week Low | $225.20 | $205.48 |
Enterprise Value | $192.92B | $27.56B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $384.98, up 0.27% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $472.29 highlight positive momentum. The company maintains robust profitability with a 26.01% net income margin and a dividend payout of $1.10, supported by solid cash flow from operations of $4.81 billion in 2025.
Outlook remains favorable with projected revenue growth to $12.7 billion in 2026, though elevated valuation ratios and competitive pressures in semiconductors pose risks. Institutional buying and a lack of sell ratings underscore confidence, but investors should monitor debt levels and market volatility.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
